South San Francisco, CA October 17, 2020 Genentech Press Release Approval supported by data from Phase III confirmatory trials, VIALE-A and VIALE-C VIALE-A study showed Venclexta plus azacitidine significantly improved overall survival in newly diagnosed AML compared to azacitidine alone…